<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Aim: This study assessed the feasibility of pelvic peritonectomy for <z:e sem="disease" ids="C0205699" disease_type="Neoplastic Process" abbrv="">carcinomatosis</z:e> localized in the pelvic cavity </plain></SENT>
<SENT sid="1" pm="."><plain>The survival and clinical benefits were examined, especially in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Seventeen patients underwent pelvic peritoneal resection for peritoneal dissemination localized in the pelvis (10 colorectal, six ovarian, one <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The male/female ratio was 5/12 </plain></SENT>
<SENT sid="4" pm="."><plain>The age range was 31-83 (median=63) years </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:e sem="disease" ids="C0153467" disease_type="Neoplastic Process" abbrv="">peritoneal cancer</z:e> index was 2-16 (median=4) </plain></SENT>
<SENT sid="6" pm="."><plain>Perioperative intraperitoneal chemotherapy was not performed </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: For <z:hpo ids='HP_0000001'>all</z:hpo> 17 cases, pelvic exenteration significantly increased invasiveness in the treatment of pelvic <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> (p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Additionally, pelvic exenteration did not improve prognosis </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases, the serum carcinoembryonic antigen (CEA) levels decreased significantly from a mean of 15.1 (range=0.8-55.7) to 2.4 (range= 0.5-7.4) ng/ml (paired t-test, p&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>For <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, serum CEA decreased significantly from 19.3 (range=1.2-55.7) to 2.7 (range=0.5-7.4) ng/ml (paired t-test, p&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>In the <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> series, cumulative 1- and 3-year overall survival rates were 89% and 71%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>One- and 3-year recurrence-free survival rates were 78% and 67%, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: The cytoreductive effect of this method is feasible and excellent for pelvic <z:e sem="disease" ids="C0205699" disease_type="Neoplastic Process" abbrv="">carcinomatosis</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Pelvic peritonectomy without perioperative intraperitoneal chemotherapy is a safe, effective procedure for <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> localized in the pelvis </plain></SENT>
</text></document>